{
    "clinical_study": {
        "@rank": "8382", 
        "acronym": "E+VIP", 
        "arm_group": [
            {
                "arm_group_label": "Concomitant:Pegasys, Euvax B, Baracrude", 
                "arm_group_type": "Experimental", 
                "description": "Peginterferon alfa-2a: once weekly 180 \u03bcg subcutaneous injection for 48 weeks\nHBV vaccination (Euvax B Inj): 1.0 mL (20 \u03bcg) intramuscular injection at 4, 8, 12 and 28 weeks\nContinue Entecavir(0.5mg) for 100 weeks(once daily)"
            }, 
            {
                "arm_group_label": "Sequential:Pegasys, Euvax B, Baracrude", 
                "arm_group_type": "Experimental", 
                "description": "Peginterferon alfa-2a: once weekly 180 \u03bcg or weight base dose subcutaneous injection for 48 weeks\nHBV vaccination (Euvax B Inj): 1.0 mL (20 \u03bcg) intramuscular injection at 52, 56, 60 and 76 weeks\nContinue Entecavir(0.5mg) for 100 weeks(once daily)"
            }, 
            {
                "arm_group_label": "Control Group", 
                "arm_group_type": "Active Comparator", 
                "description": "-Continue Entecavir(0.5mg) for 100 weeks(once daily)"
            }
        ], 
        "brief_summary": {
            "textblock": "A randomized, Open label, Single center, Prospective study to compare efficacy and safety of\n      Therapeutic Vaccination with Intensified schedule plus Pegylated Interferon dual Therapy on\n      Seroclearance of Hepatitis B virus Surface Antigen in Patients with Complete Virological\n      Response Induced by Entecavir"
        }, 
        "brief_title": "Study of Therapeutic Vaccination With Intensified Schedule Plus Pegasys Dual Therapy on Chronic Hepatitis B Infection", 
        "completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis B, Chronic", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B", 
                "Hepatitis, Chronic", 
                "Hepatitis B, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "A randomized, Open label, Single center, Prospective study to compare efficacy and safety of\n      Therapeutic Vaccination with Intensified schedule plus Pegylated Interferon dual Therapy on\n      Seroclearance of Hepatitis B virus Surface Antigen in Patients with Complete Virological\n      Response Induced by Entecavir (E + VIP)"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. age between 20 and 75 year-old\n\n          2. HBsAg-positive for > 6 months apart (medical history can be alternative)\n\n          3. currently being treated with entecavir 0.5 mg/day for more than 24 months\n\n          4. undetectable HBV DNA in serum (<20IU/mL) and HBeAg-negative for > 1year\n\n          5. HBsAg titer < 3,000 IU/mL\n\n          6. ALT<300IU/L\n\n          7. Subject must be willing to give written informed consent\n\n        Exclusion Criteria:\n\n          1. Patients with decompensated liver cirrhosis\n\n               -  serum bilirubin > 3 mg/dL\n\n               -  prothrombin time > 6 seconds prolonged or INR >2.3\n\n               -  serum albumin < 2.8 g/dL\n\n               -  History of ascites, variceal hemorrhage, or hepatic encephalopathy\n\n               -  Child-Pugh score \u22657 (Child-Pugh class B or C)\n\n          2. Patients who were treated with interferon or nucleos(t)ide analogues other than\n             Entecavir\n\n          3. Patients who have evidence of renal insufficiency defined as serum creatinine>1.5\n             mg/dL\n\n          4. Patients with psychological problem including uncontrolled depression\n\n          5. Patients who have previous/current significant co-morbidities including congestive\n             heart failure, chronic kidney disease, hematologic disease and malignancy (including\n             hepatocellular carcinoma)\n\n          6. Patients with seropositivity for anti-HCV, anti-HDV, or anti-HIV\n\n          7. Patients who have excessive alcohol consumption (> 30 g/day)\n\n          8. Patients who have evidence of autoimmune hepatitis, hemochromatosis or Wilson's\n             disease\n\n          9. Pregnant or breast feeding females\n\n         10. Patients  with disease may deteriorate with interferon therapy(eg, autoimmune\n             thyroiditis)\n\n         11. Concomitant treatment and previous organ transplantation recipients\n\n         12. Subject who the investigator deems inappropriate to participate in this study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 23, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02097004", 
            "org_study_id": "E+VIP"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Concomitant:Pegasys, Euvax B, Baracrude", 
                    "Sequential:Pegasys, Euvax B, Baracrude"
                ], 
                "description": "once weekly 180 \u03bcg subcutaneous injection for 48 weeks", 
                "intervention_name": "Peginterferon alfa-2a", 
                "intervention_type": "Biological", 
                "other_name": "Pegasys"
            }, 
            {
                "arm_group_label": [
                    "Concomitant:Pegasys, Euvax B, Baracrude", 
                    "Sequential:Pegasys, Euvax B, Baracrude"
                ], 
                "description": "1.0 mL (20 \u03bcg) intramuscular injection at 4, 8, 12 and 28 weeks", 
                "intervention_name": "HBV vaccination", 
                "intervention_type": "Biological", 
                "other_name": "Euvax B Inj"
            }, 
            {
                "arm_group_label": [
                    "Concomitant:Pegasys, Euvax B, Baracrude", 
                    "Sequential:Pegasys, Euvax B, Baracrude", 
                    "Control Group"
                ], 
                "description": "Continue Entecavir(0.5mg) for 100 weeks", 
                "intervention_name": "Entecavir", 
                "intervention_type": "Drug", 
                "other_name": "Baracrude"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Peginterferon alfa-2a", 
                "Interferon-alpha", 
                "Entecavir"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "chronic hepatitis B", 
            "Pegasys", 
            "Euvax B", 
            "Baracrude"
        ], 
        "lastchanged_date": "May 27, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "ASI/KR/KS013"
                }, 
                "name": "Seoul National University"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "3", 
        "official_title": "Phase4, to Compare Efficacy and Safety of Therapeutic Vaccination With Intensified Schedule Plus Pegylated Interferon Dual Therapy on Seroclearance of HBS Antigen in Patients With Complete Virological Response Induced by Entecavir", 
        "overall_contact": {
            "email": "yoonjun@snu.ac.kr", 
            "last_name": "Yoon Jun Kim, MD. PhD", 
            "phone": "82-2-745-1721"
        }, 
        "overall_contact_backup": {
            "email": "yunbin@hanmail.net", 
            "last_name": "Yun Bin Lee"
        }, 
        "overall_official": {
            "affiliation": "Seoul National University Hospital", 
            "last_name": "Yoon Jun Kim, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The rate of HBsAg-seroclearance at the time point of at weeks 72 in the concomitant treatment group and at weeks 100 in the sequential treatment group (24 weeks after termination of treatment)", 
            "measure": "The rate of HBsAg-seroclearance", 
            "safety_issue": "No", 
            "time_frame": "The rate of HBsAg-seroclearance at the time point of at weeks 72"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02097004"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Seoul National University Hospital", 
            "investigator_full_name": "Yoon Jun Kim", 
            "investigator_title": "MD, PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The rate of HBsAg-seroconversion at weeks 72 in theconcomitant treatment group and at weeks 100 in the sequential treatment group", 
                "measure": "The rate of HBsAg-seroconversion", 
                "safety_issue": "No", 
                "time_frame": "The rate of HBsAg-seroconversion at weeks 72"
            }, 
            {
                "description": "The Change of HBsAg level from baseline at weeks 72 in the concomitant treatment group and at weeks 100 in the sequential treatment group", 
                "measure": "The Change of HBsAg level from baseline", 
                "safety_issue": "No", 
                "time_frame": "The Change of HBsAg level from baseline at weeks 72"
            }
        ], 
        "source": "Seoul National University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Seoul National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}